Carboplatin 450mg/45ml injection
Ferron Par Pharmaceuticals
Ingredients in every 45 ml
Each package contains
|ATC Level 1||L - Antineoplastic and immunomodulating agents|
|ATC Level 2||L01 - Antineoplastic Agents|
|ATC Level 3||L01X - Other Antineoplastic Agents in ATC|
18 YEARS OLD AND ABOVE
The recommended dose of carboplatin in previously untreated adults patients with normal kidney is 400 mg/m² as a single intravenous infusion over 15-60 minutes.
Therapy should not be repeated until four weeks after the previous carboplatin course and/or the neutrophil count is at least 2,000 cells/mm³ and the platelet count is at least 100,000 cells/mm³.
It is recommended that according to clinical circumstances, the initial dosage may require reduction by 20-25% in patients with risk factors such as previous myelosuppressive therapy and poor performance status.
Determination of hematological nadir by weekly blood counts during initial courses is recommended for future dosage adjustment and scheduling of carboplatin.
The optimal use of carboplatin in combination with other myelosuppressive agents requires dosage adjustments according to the regimen and schedule to be adopted.
– Advanced ovarian carcinoma
– Small cell and non-small cell carcinoma of the lung
– Squamous cell carcinoma of the head and neck
– Advanced transitional cell carcinoma of the bladder
– Significant responses have been observed when carboplatin employed in the treatment of carcinoma of the cervix
Carboplatin is frequently used in combination with other chemotherapeutic agent in various indications, such as with paclitaxel in first line therapy of ovarian carcinoma and non-small cell lung carcinoma.